March 24, 2026 — Genflow Biosciences (LON: GENF) has announced new funding to support the advancement of its gene therapy pipeline targeting age-related diseases. The company revealed it has raised approximately £800,000 through an equity issue while also receiving the first tranche of a €4 million non-dilutive grant, reflecting growing investor and institutional interest in therapies designed to extend healthy lifespan.
The new capital will provide near-term operational support as Genflow progresses its research programs focused on the biological mechanisms underlying ageing. Early-stage biotechnology companies often rely on a combination of equity financing and grant funding to sustain development before reaching major clinical milestones. Genflow’s ability to secure both private investment and public funding highlights confidence in its scientific strategy and development roadmap.
The £800,000 equity raise will help fund key operational activities, including preclinical development and regulatory preparation for the company’s gene therapy candidates. Participation by PDMRs (Persons Discharging Managerial Responsibilities) in the offering may also signal internal confidence in the company’s direction and future prospects.
Alongside the equity financing, Genflow Biosciences has secured the first tranche of a €4 million grant, providing important non-dilutive funding that enables the company to advance research without issuing additional shares. Such grants are typically awarded following detailed scientific evaluations, suggesting recognition of the potential impact of Genflow’s work in targeting ageing-related biological pathways.
Genflow operates within the rapidly emerging longevity biotechnology sector, where researchers are exploring therapies that address the root causes of age-associated diseases rather than treating individual symptoms. Central to this strategy is the development of gene therapy approaches using adeno-associated virus (AAV) vectors, which are widely used for delivering therapeutic genes with long-term expression and favorable safety profiles.
By leveraging AAV-based gene delivery, Genflow aims to regulate or restore gene function associated with ageing processes and age-related diseases. Advances in gene delivery technologies such as AAV vectors are enabling scientists to explore new therapeutic strategies for conditions that were previously difficult to treat.
As global populations continue to age, the demand for therapies that extend health span—the period of life spent in good health—has increased significantly. Gene therapy platforms, including AAV vectors, are becoming an important tool in this effort by allowing researchers to target the molecular drivers of ageing at their genetic roots.
The company’s dual funding strategy reflects broader financing trends across the biotechnology sector. Early-stage biotech companies often combine equity raises with government or institutional grants to maintain development momentum while minimizing shareholder dilution. European funding bodies in particular have increased their support for innovative healthcare technologies addressing long-term demographic challenges such as ageing populations.
With additional capital now secured, Genflow Biosciences plans to continue advancing its AAV gene therapy programs through key preclinical milestones aimed at establishing safety and efficacy before entering clinical development.
By combining new equity investment with significant grant support, Genflow Biosciences has strengthened its financial position as it continues to develop AAV-based gene therapies targeting the biological drivers of ageing and age-related diseases.
